Tiziana Life Sciences is trading 6.58% higher at $0.68 in after-hours trading, with no specific catalyst identified. - It closed the November 4 regular session at $0.64, down 7.55%. - Recent Phase 2a results showed the 50-µg dose reduced microglial activation; the 100-µg dose did not significantly beat placebo on that measure. - Broader U.S. indexes gained, but the earlier results do not clearly explain the after-hours rise.